denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.
Program: How I Treat
Sunday, December 8, 2024: 8:00 AM-9:00 AM
Aqua 311
(Hilton San Diego Bayfront)
Speaker:
Michael R Bishop, MD, University of Chicago
Disclosures:
Bishop: Iovance Biotherapeutics: Consultancy; AstraZeneca: Honoraria, Speakers Bureau; Servier: Consultancy, Honoraria, Speakers Bureau; GenMab: Honoraria, Speakers Bureau; ADC Therapeutics: Honoraria, Speakers Bureau; Incyte: Honoraria; Achieve Clinics, Arcellx, Autolus, BMS, Chimeric Therapeutics, CRISPR Therapeutics, In8Bio, Iovance Biotherapeutics, Kite-Gilead, Optum Health, Novartis, Sana Biotechnology: Consultancy; Achieve Clinics, In8Bio: Current holder of stock options in a privately-held company; Arcellx, Autolus, Bristol-Myers Squibb, CRISPR Therapeutics, Lyell, Gilead Sciences and Novartis: Research Funding; AbbVie, ADC Therapeutics, Bristol-Myers Squibb, Gilead Sciences, Incyte, Novartis, Sanofi and Servier: Honoraria, Speakers Bureau; Sana Biotechnology: Consultancy, Honoraria; Galapagos: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; In8bio: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Chimeric Therapeutics: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Bristol-Meyer-Squibb: Consultancy, Honoraria, Speakers Bureau; CRISPR Therapeutics: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Kite/Gilead: Consultancy, Honoraria, Research Funding, Speakers Bureau.
See more of: How I Treat